Information on revision of the Medical Devices Law in Switzerland

After various incidents the control mechanisms for medical devices are being reinforced throughout Europe. Switzerland is also revising its medical devices legislation, closely modelled on the various new EU-requirements, with the aim of improving the safety and quality of medical devices. Up-to-date information (in English) can be found via THIS LINK. Let us know if […]

EMA’s new Q&A re: orphan medicines

EMA has recently published a question-and-answer document, addressing common misunderstandings about the meaning of orphan designation and other aspects pertaining to orphan medicines. Here we have a document that explains key concepts in the regulation of medicines for rare diseases such as orphan designation and significant benefit. Hemex frequently submits ODD applications for Sponsors of […]

InnoSuisse Roadshow

Switzerland is the leading nation for innovation for several years in a row, according to the Geneva-based World Intellectual Property Organization (WIPO). The other countries in the top five for 2017 were Sweden, the Netherlands, the United States and Britain. (WIPO global innovation index). Switzerland has held the top spot since 2011. Events like the […]

Non-Dilutive Research Funding available!

Non-Dilutive Research Funding for Swiss Biotech companies The Swiss Biotech Association invited HEMEX to an information event on 12 March 2018 in Bern (Switzerland), regarding the possibilities Swiss biotech companies have for accessing different national and international non-dilutive funding instruments. Our customer solutions team attended the presentations and would be happy to show you the different […]